Suppr超能文献

关于荨麻疹管理的共识声明。

Consensus statement on the management of urticaria.

作者信息

Godse Kiran V, Zawar Vijay, Krupashankar Ds, Girdhar Mukesh, Kandhari Sanjiv, Dhar Sandipan, Ghosh Sanjay, Rajagopalan Murlidhar, Zuberbier Torsten

机构信息

Form the Shree Skin Centre & Pathology Laboratory, Nerul, Navi Mumbai, India.

出版信息

Indian J Dermatol. 2011 Sep-Oct;56(5):485-9. doi: 10.4103/0019-5154.87119.

Abstract

This consensus statement was developed by Special Interest Group - Urticaria (IADVL). Urticaria, a heterogeneous group of diseases, often cannot be recognized by its morphology. Due to non-specific and non-affordable diagnosis, management of urticaria, especially chronic urticaria, is very challenging. This guideline includes definition, causes, classification and management of urticaria. Urticaria has a profound impact on the quality of life and causes immense distress to patients, necessitating effective treatment. One approach to manage urticaria is identification and elimination of the underlying cause(s) and/or eliciting trigger(s), while the second one is treatment aimed at providing symptomatic relief. This guideline recommends use of second-generation non-sedating H1 antihistamines as the first-line treatment. The dose can be increased up to four times to meet the expected results. In case patients still do not respond, appropriate treatment options can be selected depending on the cost.

摘要

本共识声明由国际皮肤科联盟(IADVL)荨麻疹特别兴趣小组制定。荨麻疹是一组异质性疾病,通常无法通过其形态学特征来识别。由于诊断缺乏特异性且费用高昂,荨麻疹尤其是慢性荨麻疹的管理极具挑战性。本指南涵盖了荨麻疹的定义、病因、分类和管理。荨麻疹对生活质量有深远影响,给患者带来极大痛苦,因此需要有效治疗。管理荨麻疹的一种方法是识别并消除潜在病因和/或诱发因素,另一种方法是进行旨在缓解症状的治疗。本指南推荐使用第二代非镇静性H1抗组胺药作为一线治疗药物。剂量可增加至四倍以达到预期效果。如果患者仍无反应,可根据费用选择合适的治疗方案。

相似文献

1
Consensus statement on the management of urticaria.
Indian J Dermatol. 2011 Sep-Oct;56(5):485-9. doi: 10.4103/0019-5154.87119.
2
Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.
Indian J Dermatol. 2018 Jan-Feb;63(1):2-15. doi: 10.4103/ijd.IJD_308_17.
3
Diagnosis and Management of Urticaria in Indian Settings: Skin Allergy Research Society's Guideline-2022.
Indian J Dermatol. 2022 Nov-Dec;67(6):732-743. doi: 10.4103/ijd.ijd_307_22.
4
S3 Guideline Urticaria. Part 2: Treatment of urticaria - German-language adaptation of the international S3 guideline.
J Dtsch Dermatol Ges. 2023 Feb;21(2):202-215. doi: 10.1111/ddg.14932. Epub 2023 Feb 2.
5
Management of chronic urticaria in Asia: 2010 AADV consensus guidelines.
Asia Pac Allergy. 2012 Apr;2(2):149-60. doi: 10.5415/apallergy.2012.2.2.149. Epub 2012 Apr 30.
7
Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.
J Eur Acad Dermatol Venereol. 2012 Jan;26(1):9-18. doi: 10.1111/j.1468-3083.2011.04185.x. Epub 2011 Jul 29.
9
Antihistamines in urticaria.
Clin Exp Allergy. 1999 Mar;29 Suppl 1:31-7. doi: 10.1046/j.1365-2222.1999.00006.x.
10
Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
Actas Dermosifiliogr. 2017 May;108(4):346-353. doi: 10.1016/j.ad.2016.12.012. Epub 2017 Feb 20.

引用本文的文献

1
Diagnosis and Management of Urticaria in Indian Settings: Skin Allergy Research Society's Guideline-2022.
Indian J Dermatol. 2022 Nov-Dec;67(6):732-743. doi: 10.4103/ijd.ijd_307_22.
2
Institute of Child Health, Kolkata, 1956-2022.
Indian Pediatr. 2022 Sep 15;59(9):734-739. doi: 10.1007/s13312-022-2613-3.
3
Computer-assisted Medical Decision-making System for Diagnosis of Urticaria.
MDM Policy Pract. 2016 Nov 9;1(1):2381468316677752. doi: 10.1177/2381468316677752. eCollection 2016 Jul-Dec.
4
Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria.
J Clin Diagn Res. 2017 Mar;11(3):WC06-WC09. doi: 10.7860/JCDR/2017/23961.9550. Epub 2017 Mar 1.
5
Updosing of Nonsedating Anti-histamines in Recalcitrant Chronic Urticaria.
Indian J Dermatol. 2016 May-Jun;61(3):273-8. doi: 10.4103/0019-5154.182406.
6
Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients.
Indian Dermatol Online J. 2016 Jan-Feb;7(1):6-11. doi: 10.4103/2229-5178.174314.
7
Food hypersensitivity in patients over 14 years of age suffering from atopic dermatitis.
Indian J Dermatol. 2014 May;59(3):316. doi: 10.4103/0019-5154.131446.
10
Chronic urticaria: Indian context-challenges and treatment options.
Dermatol Res Pract. 2013;2013:651737. doi: 10.1155/2013/651737. Epub 2013 Sep 24.

本文引用的文献

1
Fexofenadine in higher doses in chronic spontaneous urticaria.
Indian Dermatol Online J. 2010 Jul;1(1):45-6. doi: 10.4103/2229-5178.73262.
2
Cyclosporine-A in severe chronic urticaria: the option for long-term therapy.
Allergy. 2010 Nov;65(11):1478-82. doi: 10.1111/j.1398-9995.2010.02419.x.
3
Safety of antihistamines during pregnancy and lactation.
Can Fam Physician. 2010 May;56(5):427-9.
4
Chronic urticaria and treatment options.
Indian J Dermatol. 2009;54(4):310-2. doi: 10.4103/0019-5154.57603.
5
Updosing of antihistamines to improve control of chronic urticaria.
Indian J Dermatol Venereol Leprol. 2010 Jan-Feb;76(1):61-2. doi: 10.4103/0378-6323.58684.
6
Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria.
Br J Dermatol. 2010 Jan;162(1):191-4. doi: 10.1111/j.1365-2133.2009.09538.x. Epub 2009 Nov 6.
7
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.
Allergy. 2009 Oct;64(10):1427-1443. doi: 10.1111/j.1398-9995.2009.02178.x.
8
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.
Allergy. 2009 Oct;64(10):1417-1426. doi: 10.1111/j.1398-9995.2009.02179.x.
9
Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.
Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验